Reviewing the role of the genes G72 and DAAO in glutamate neurotransmission in schizophrenia

European Neuropsychopharmacology

Volumn 17, Issue 9, 2007, Pages 567-572

  Boks, M P M ^a   Rietkerk, T ^a   van de Beek, M H ^a   Sommer, I E ^a   de Koning, T J ^a   Kahn, R S ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

D Serine; DAAO; ; G72; ; Glutamate; ; Schizophrenia;

Indexed keywords

DEXTRO AMINO ACID OXIDASE; DEXTRO SERINE; GENE PRODUCT; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SERINE;

ADD ON THERAPY; CELL DEATH; CELL MIGRATION; CONTROLLED STUDY; G72 GENE; GENE; GENETIC SUSCEPTIBILITY; HUMAN; NERVE CELL; NEUROTRANSMISSION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

CARRIER PROTEINS; D-AMINO-ACID OXIDASE; GENETIC PREDISPOSITION TO DISEASE; GLUTAMIC ACID; HUMANS; MODELS, BIOLOGICAL; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 34447550448     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2006.12.003     Document Type: Review

References (53)

1. Andersen J.D., and Pouzet B. Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of D-serine. Neuropsychopharmacology 29 (2004) 1080-1090
2. Chumakov I., Blumenfeld M., Guerassimenko O., Cavarec L., Palicio M., Abderrahim H., Bougueleret L., Barry C., Tanaka H., La R.P., Puech A., Tahri N., Cohen-Akenine A., Delabrosse S., Lissarrague S., Picard F.P., Maurice K., Essioux L., Millasseau P., Grel P., Debailleul V., Simon A.M., Caterina D., Dufaure I., Malekzadeh K., Belova M., Luan J.J., Bouillot M., Sambucy J.L., Primas G., Saumier M., Boubkiri N., Martin-Saumier S., Nasroune M., Peixoto H., Delaye A., Pinchot V., Bastucci M., Guillou S., Chevillon M., Sainz-Fuertes R., Meguenni S., urich-Costa J., Cherif D., Gimalac A., Van D.C., Gauvreau D., Ouellette G., Fortier I., Raelson J., Sherbatich T., Riazanskaia N., Rogaev E., Raeymaekers P., Aerssens J., Konings F., Luyten W., Macciardi F., Sham P.C., Straub R.E., Weinberger D.R., Cohen N., and Cohen D. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 13675-13680
3. De M.J., Panizzutti R., Foltyn V.N., and Wolosker H. Cofactors of serine racemase that physiologically stimulate the synthesis of the N-methyl-D-aspartate (NMDA) receptor coagonist D-serine. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 14542-14547
4. Detera-Wadleigh S.D., and McMahon F.J. G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis. Biol. Psychiatry (2006)
5. Duncan E.J., Szilagyi S., Schwartz M.P., Bugarski-Kirola D., Kunzova A., Negi S., Stephanides M., Efferen T.R., Angrist B., Peselow E., Corwin J., Gonzenbach S., and Rotrosen J.P. Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophr. Res. 71 (2004) 239-248
6. Evins A.E., Amico E., Posever T.A., Toker R., and Goff D.C. D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr. Res. 56 (2002) 19-23
7. Foltyn V.N., Bendikov I., De M.J., Panizzutti R., Dumin E., Shleper M., Li P., Toney M.D., Kartvelishvily E., and Wolosker H. Serine racemase modulates intracellular D-serine levels through an alpha,beta-elimination activity. J. Biol. Chem. 280 (2005) 1754-1763
8. Fuchs S.A., Berger R., Klomp L.W., and de Koning T.J. D-amino acids in the central nervous system in health and disease. Mol. Genet. Metab. 85 (2005) 168-180
9. Goff D.C., Tsai G., Levitt J., Amico E., Manoach D., Schoenfeld D.A., Hayden D.L., McCarley R., and Coyle J.T. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psychiatry 56 (1999) 21-27
10. Goldberg T.E., Straub R.E., Callicott J.H., Hariri A., Mattay V.S., Bigelow L., Coppola R., Egan M.F., and Weinberger D.R. The G72/G30 gene complex and cognitive abnormalities in schizophrenia. Neuropsychopharmacology (2006)
11. Goltsov A.Y., Loseva J.G., Andreeva T.V., Grigorenko A.P., Abramova L.I., Kaleda V.G., Orlova V.A., Moliaka Y.K., and Rogaev E.I. Polymorphism in the 5′-promoter region of serine racemase gene in schizophrenia. Mol. Psychiatry 11 (2006) 325-326
12. Grimwood S., Slater P., Deakin J.F., and Hutson P.H. NR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia. NeuroReport 10 (1999) 461-465
13. Hamase K., Nagayasu R., Morikawa A., Konno R., and Zaitsu K. Sensitive high-performance liquid chromatographic assay for D-amino-acid oxidase activity in mammalian tissues using a fluorescent non-natural substrate, 5-fluoro-D-tryptophan. J. Chromatogr. A 1106 (2006) 159-164
14. Harsing Jr. L.G., Juranyi Z., Gacsalyi I., Tapolcsanyi P., Czompa A., and Matyus P. Glycine transporter type-1 and its inhibitors. Curr. Med. Chem. 13 (2006) 1017-1044
15. Hashimoto A., and Oka T. Free D-aspartate and D-serine in the mammalian brain and periphery. Prog Neurobiol. 52 (1997) 325-353
16. Hashimoto A., Kumashiro S., Nishikawa T., Oka T., Takahashi K., Mito T., Takashima S., Doi N., Mizutani Y., and Yamazaki T. Embryonic development and postnatal changes in free D-aspartate and D-serine in the human prefrontal cortex. J. Neurochem. 61 (1993) 348-351
17. Hashimoto K., Fukushima T., Shimizu E., Komatsu N., Watanabe H., Shinoda N., Nakazato M., Kumakiri C., Okada S., Hasegawa H., Imai K., and Iyo M. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry 60 (2003) 572-576
18. Hashimoto K., Engberg G., Shimizu E., Nordin C., Lindstrom L.H., and Iyo M. Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 29 (2005) 767-769
19. Heresco-Levy U., and Javitt D.C. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr. Res. 66 (2004) 89-96
20. Heresco-Levy U., Ermilov M., Shimoni J., Shapira B., Silipo G., and Javitt D.C. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am. J. Psychiatry 159 (2002) 480-482
21. Heresco-Levy U., Javitt D.C., Ebstein R., Vass A., Lichtenberg P., Bar G., Catinari S., and Ermilov M. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol. Psychiatry 57 (2005) 577-585
22. Horiike K., Tojo H., Arai R., Nozaki M., and Maeda T. D-amino-acid oxidase is confined to the lower brain stem and cerebellum in rat brain: regional differentiation of astrocytes. Brain Res. 652 (1994) 297-303
23. Hulshoff Pol H.E., Schnack H.G., Bertens M.G., van Haren N.E., van der Tweel I., Staal W.G., Baare W.F., and Kahn R.S. Volume changes in gray matter in patients with schizophrenia. Am. J. Psychiatry 159 (2002) 244-250
24. Ishimaru M., Kurumaji A., and Toru M. NMDA-associated glycine binding site increases in schizophrenic brains. Biol. Psychiatry 32 (1992) 379-381
25. Johnson J.W., and Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325 (1987) 529-531
26. Kartvelishvily E., Shleper M., Balan L., Dumin E., and Wolosker H. Neuron-derived D-serine: Novel means to activate N-methyl-D-aspartate receptors. J. Biol. Chem. (2006)
27. Katagiri M., Tojo H., Horiike K., and Yamano T. Immunochemical relationship of D-amino acid oxidases in various tissues and animals. Comp. Biochem. Physiol. B 99 (1991) 345-350
28. Katsuki H., Nonaka M., Shirakawa H., Kume T., and Akaike A. Endogenous D-serine is involved in induction of neuronal death by N-methyl-D-aspartate and simulated ischemia in rat cerebrocortical slices. J. Pharmacol. Exp. Ther. 311 (2004) 836-844
29. Kim P.M., Aizawa H., Kim P.S., Huang A.S., Wickramasinghe S.R., Kashani A.H., Barrow R.K., Huganir R.L., Ghosh A., and Snyder S.H. Serine racemase: activation by glutamate neurotransmission via glutamate receptor interacting protein and mediation of neuronal migration. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 2105-2110
30. Korostishevsky M., Kaganovich M., Cholostoy A., Ashkenazi M., Ratner Y., Dahary D., Bernstein J., ing-Abu-Shach U., Ben-Asher E., Lancet D., Ritsner M., and Navon R. Is the G72/G30 locus associated with schizophrenia? Single nucleotide polymorphisms, haplotypes, and gene expression analysis. Biol. Psychiatry 56 (2004) 169-176
31. Kumashiro S., Hashimoto A., and Nishikawa T. Free D-serine in post-mortem brains and spinal cords of individuals with and without neuropsychiatric diseases. Brain Res. 681 (1995) 117-125
32. Lo E.H., Pierce A.R., Matsumoto K., Kano T., Evans C.J., and Newcomb R. Alterations in K+ evoked profiles of neurotransmitter and neuromodulator amino acids after focal ischemia-reperfusion. Neuroscience 83 (1998) 449-458
33. Mohn A.R., Gainetdinov R.R., Caron M.G., and Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98 (1999) 427-436
34. Moreno S., Nardacci R., Cimini A., and Ceru M.P. Immunocytochemical localization of D-amino acid oxidase in rat brain. J. Neurocytol. 28 (1999) 169-185
35. Mothet J.P., Parent A.T., Wolosker H., Brady Jr. R.O., Linden D.J., Ferris C.D., Rogawski M.A., and Snyder S.H. D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 4926-4931
36. Owen M.J., Williams N.M., and O'Donovan M.C. The molecular genetics of schizophrenia: new findings promise new insights. Mol. Psychiatry 9 (2004) 14-27
37. Park H.K., Shishido Y., Ichise-Shishido S., Kawazoe T., Ono K., Iwana S., Tomita Y., Yorita K., Sakai T., and Fukui K. Potential role for astroglial D-amino acid oxidase in extracellular D-serine metabolism and cytotoxicity. J. Biochem. (Tokyo) 139 (2006) 295-304
38. Schell M.J., Molliver M.E., and Snyder S.H. D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 3948-3952
39. Schell M.J., Brady Jr. R.O., Molliver M.E., and Snyder S.H. D-serine as a neuromodulator: regional and developmental localizations in rat brain glia resemble NMDA receptors. J. Neurosci. 17 (1997) 1604-1615
40. Schiffer H.H. Glutamate receptor genes: susceptibility factors in schizophrenia and depressive disorders?. Mol. Neurobiol. 25 (2002) 191-212
41. Shleper M., Kartvelishvily E., and Wolosker H. D-serine is the dominant endogenous coagonist for NMDA receptor neurotoxicity in organotypic hippocampal slices. J. Neurosci. 25 (2005) 9413-9417
42. Snyder S.H., and Ferris C.D. Novel neurotransmitters and their neuropsychiatric relevance. Am. J. Psychiatry. 157 (2000) 1738-1751
43. Stevens E.R., Esguerra M., Kim P.M., Newman E.A., Snyder S.H., Zahs K.R., and Miller R.F. D-serine and serine racemase are present in the vertebrate retina and contribute to the physiological activation of NMDA receptors. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 6789-6794
44. Tsai G., Ralph-Williams R.J., Martina M., Bergeron R., Berger-Sweeney J., Dunham K.S., Jiang Z., Caine S.B., and Coyle J.T. Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 8485-8490
45. Tuominen H.J., Tiihonen J., and Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 72 (2005) 225-234
46. Volpe J.J., Lee G., Laster L., and Robinson J.C. Regional distribution of isozymes of D-amino-acid oxidase and acetylesterase in developing primate brain. Exp. Neurol. 28 (1970) 76-87
47. Wake K., Yamazaki H., Hanzawa S., Konno R., Sakio H., Niwa A., and Hori Y. Exaggerated responses to chronic nociceptive stimuli and enhancement of N-methyl-D-aspartate receptor-mediated synaptic transmission in mutant mice lacking D-amino-acid oxidase. Neurosci. Lett. 297 (2001) 25-28
48. Williams N.M., Green E.K., Macgregor S., Dwyer S., Norton N., Williams H., Raybould R., Grozeva D., Hamshere M., Zammit S., Jones L., Cardno A., Kirov G., Jones I., O'Donovan M.C., Owen M.J., and Craddock N. Variation at the DAOA/G30 locus influences susceptibility to major mood episodes but not psychosis in schizophrenia and bipolar disorder. Arch. Gen. Psychiatry 63 (2006) 366-373
49. Williams S.M., Diaz C.M., Macnab L.T., Sullivan R.K., and Pow D.V. Immunocytochemical analysis of D-serine distribution in the mammalian brain reveals novel anatomical compartmentalizations in glia and neurons. Glia 53 (2006) 401-411
50. Wolosker H., Blackshaw S., and Snyder S.H. Serine racemase: a glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 13409-13414
51. Yamada K., Ohnishi T., Hashimoto K., Ohba H., Iwayama-Shigeno Y., Toyoshima M., Okuno A., Takao H., Toyota T., Minabe Y., Nakamura K., Shimizu E., Itokawa M., Mori N., Iyo M., and Yoshikawa T. Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels. Biol. Psychiatry 57 (2005) 1493-1503
52. Yoshikawa M., Andoh H., Ito K., Suzuki T., Kawaguchi M., Kobayashi H., Oka T., and Hashimoto A. Acute treatment with morphine augments the expression of serine racemase and D-amino acid oxidase mRNAs in rat brain. Eur. J. Pharmacol. 525 (2005) 94-97
53. Yurgelun-Todd D.A., Coyle J.T., Gruber S.A., Renshaw P.F., Silveri M.M., Amico E., Cohen B., and Goff D.C. Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine. Psychiatry Res. 138 (2005) 23-31